Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2011-08-30
2011-08-30
Ton, Thaian N (Department: 1632)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007100, C435S455000, C435S375000
Reexamination Certificate
active
08007994
ABSTRACT:
The present invention relates to compositions and methods for reducing cholesterolemia and its effects. More specifically, the invention is directed, in one embodiment, to methods for screening for compounds that affect cholesterol levels generally, and in particular, that affect the absorption of cholesterol. The invention also is directed to methods of screening for compounds that increase bile acid synthesis. In so doing, the inventors describe useful transgenic cells and animals which lack one or both alleles of the LXRα gene. Also provided are therapeutic methods designed to reduce cholesterol levels in suitable subjects. The reduction may be effected by decreasing cholesterol absorption, increasing bile acid synthesis, or combinations thereof. Particularly useful in decreasing cholesterol absorption are RXR agonists, for example, rexinoid compounds. Therapeutic intervention in cholesterol biosynthesis and diet are additional adjunct therapies. In addition, the present invention relates to candidate compounds that modulate the expression of ABC-1 in a cell that expresses RXR. Methods of identifying and making a modulator of ABC-1 are disclosed.
REFERENCES:
patent: 4430434 (1984-02-01), Sanders et al.
patent: 4559302 (1985-12-01), Ingolia
patent: 4727028 (1988-02-01), Santerre et al.
patent: 4960704 (1990-10-01), Ingolia et al.
patent: 5354855 (1994-10-01), Cech et al.
patent: 5697899 (1997-12-01), Hillman et al.
patent: 5779708 (1998-07-01), Wu
patent: 5780676 (1998-07-01), Boehm et al.
patent: 5783208 (1998-07-01), Venkateshwaran et al.
patent: 5789655 (1998-08-01), Prusiner et al.
patent: 5797898 (1998-08-01), Santini, Jr. et al.
patent: 0273085 (1986-12-01), None
Oram, et al, Journal of Lipid Research, 42: 1173-1179, 2001.
Repa et al, Science, 289: 1524-1529, 2000.
Chernobelsky, et al, Preventive Cardiology, 10: 26-30, 2007.
Broedl et al, Expert Opin Biol Ther, 5(8): 1029-1038, 2005.
Young et al, (Nature Genetics, 22: 326-318, 1999.
Ecke et al , Goodman & Gilman's The Pharmacological basis of Therapeutics, McGraw-Hill, New York, NY. pp. 77-101.
Accad and Farese Jr.,“Cholesterol homeostasis: a role for oxysterols”.Curr. Biol.8:R601-R604, 1998.
Androlewicz et al.,“Characteristics of peptide and major histocompatibility complex class I/β2-microglobulin binding to the transporters associated with antigen processing (TAP1 and TAP2),”Proc.Natl. Acad. Sci. USA 91:12716-12720, 1994.
Beato et al., “Steroid hormone receptors: many actors in search of a plot”Cell, 83:851-857, 1995.
Bodzioch et al. “The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease,”Nat. Genet. 22:347-351, 1999.
Boehm et al.,“Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells.”J. Med. Chem. 38:3146-3155, 1995.
Brooks-Wilson et al. “Mutations inABCIin Tangier disease and familial high-density lipoprotein deficiency,”Nat. Genet. 22:336-345, 1999.
Brown and Goldstein, “The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor,”Cell, 89:331-340, 1997.
Buchler et al.,“cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats,”J. Biol. Chem. 271(25):15091-15098, 1996.
Bugge et al., “RXRα, a promiscuous partner of retinoic and thyroid hormone receptors,”EMBO J., 11(4):1409-1418, 1992.
Chiang and Stroup, “Identification and characterization of a putative bile acid-responsive element in cholesterol 7α-hydroxylase gene promoter,”J. Biol. Chem., 269(26):17502-17507, 1994.
D. Mangelsdorf et al. “The rxr heterodimers and orphan receptors,”Cell, 83:841-850, 1995.
Evans et al., “The steroid and thyroid hormone receptor superfamily”Science, 240:889-895, 1988.
Field et al.,“Caveolin is present in intestinal cells: role in cholesterol trafficking?”J. Lipid Res. 39:1938-1950, 1998.
Forman et al., “A domain containing leucine-zipper-like motifs mediate novel in Vivo interactions between the thyroid hormone and retinoic acid receptors,”Mol. Endocrinol., 3:(10)1610-1626, 1989.
Forman et al., “Unique response pathways are established by allosteric interacions among nuclear hormone receptors,”Cell, 81:541-550, 1995.
Forman et al.,Cell,“Identification of a nuclear receptor that is activated by fame sol metabolites,” 81:687-693, 1995.
Forman et al.,“15-Deoxy-Δ12, 14-prostaglandin J2is a ligand for the adipocyte determination factor PPARγ,”Cell, 83(5):803-812, 1995b.
Francis et al., “Defective removal of cellular cholesteral and phospholipids by apolipoprotein A-1 in Tangier disease,”J. Clin. Invest. 96:78-87,1995.
Glass, “Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers,”Endocrine Rev., 15(3):391-407, 1994.
Hersdorffer et al., “Efficient gene transfer in live mice using a unique retroviral packaging line,”DNA Cell Biol., 9(10):713-723, 1990.
Higgins, “ABC transporters: from microorganisms to man,”Annu. Rev. Cell Biol. 8:67-113, 1992.
Homan and Krause, “Established and emerging strategies for the inhibition of cholesterol absorption.” 'Curr. Pharmaceut. Design3:29-44, 1997.
Ishibashi et al., “Disruption of cholesterol 7α-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation,”J. Biol. Chem., 271(30):18017-18023, 1996.
Ishibashi et al., “Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery,”J. Clin. Invest., 92:883-893, 1993.
Janowski et al., “An oxysterol signaling pathway mediated by the nuclear receptor LXRα,”Nature, 383:728-731, 1996.
Kliewer et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,”Proc. Natl. Acad. Sci USA, 91:7355-7359, 1994.
Kliewer et al., “Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3signalling,”Nature, 355: 446-449, 1992.
Kliewer et al.,“Convergence of 9-cisretinoic acid and peroxisome proliferater signalling pathways through heterodimer formation of their receptors,”Nature, 358:771-774, 1992.
Kurokawa et al., “Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding,”Nature, 371:528-531, 1994.
Kurokawa et at.,“Differential orientations of the DNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers,”Genes Dev., 7:1423-1435, 1993.
Kurokawa et al.,“Polarity-specific activities of retinoic acid receptors determined by a co-repressor,”Nature, 377:451-454, 1995.
Langmann et al. “Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages,”Biochem. Biophys. Res. Commun. 257:29-33, 1999.
Lawn et al. “The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway,”J. Clin. Invest. 104:R25-R31, 1999.
Leblanc & Stunnenberg,“9-Cisretinoic acid signaling: changing partners causes some excitement,”Genes Dev., 9:1811-1816, 1995.
Lehmann et al., “Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway,”J. Biol. Chem., 272(6):3137-3140, 1997.
Lehrman et al., “Alu-Alu recombination deletes splice acceptor sites and produces secreted low density lipoprotein receptor in a subject with familial hypercholesterolemia,”J. Biol. Chem., 262(7):3354-3361, 1987.
Leid et al., “Multiplicity generate
Dietschy John M.
Mangelsdorf David J.
Repa Joyce J.
Turley Stephen D.
Fulbright & Jaworski
Sgagias Magdalene
The Board of Regents of the University of Texas System
Ton Thaian N
LandOfFree
Compositions and methods of modulating cholesterol metabolism does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods of modulating cholesterol metabolism, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of modulating cholesterol metabolism will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747868